Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19
HOS-134021 · Präparat HOS-097520
18 Medicinal product by Effects on medicinal product Recommendation concerning therapeutic areas levels. co-administration with Genvoya Mean percent change in AUC, Cmax, Cmin1 Pravastatin Interaction not studied with any of Dose modifications are not Fluvastatin the components of Genvoya. necessary when administered in combination with Genvoya. Concentrations of these HMG Co-A reductase inhibitors are expected to transiently increase when administered with elvitegravir and cobicistat. Lovastatin Interaction not studied with any of Co-administration of Genvoya and Simvastatin the components of Genvoya. lovastatin and simvastatin is contraindicated (see section 4.3). LIPID-MODIFYING AGENTS Lomitapide Interaction not studied with any of Coadministration with lomitapide is the components of Genvoya. contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 324f5a649d9a139c08caf58f8daef9e1c1f8b6a2ec71552eb5f5622353a4ddae · Zeichen 41462–43018 im Abschnitt